Press Releases Keyword Search Year None202120202019201820172016201520142013 September 8, 2021 Editas Medicine Names Emma Reeve to Board of Directors September 7, 2021 Initial Clinical Data from Editas Medicine’s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September September 2, 2021 Editas Medicine to Participate in Upcoming Investor Conferences August 20, 2021 Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Meeting August 4, 2021 Editas Medicine Announces Second Quarter 2021 Results and Business Updates July 29, 2021 Editas Medicine and IDT Announce Publication in Nature Communications of Research Data Supporting the Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the Potential of Gene-Edited Cell Medicines July 28, 2021 Editas Medicine to Host Conference Call Discussing Second Quarter 2021 Results and Corporate Update July 26, 2021 Editas Medicine Names Bruce E. Eaton, Ph.D., as Executive Vice President and Chief Business Officer June 23, 2021 Editas Medicine Announces Enrollment of the First Pediatric Cohort in the BRILLIANCE Clinical Trial of EDIT-101 for the Treatment of LCA10 Following IDMC Endorsement June 15, 2021 Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
September 7, 2021 Initial Clinical Data from Editas Medicine’s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September
August 20, 2021 Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Meeting
July 29, 2021 Editas Medicine and IDT Announce Publication in Nature Communications of Research Data Supporting the Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the Potential of Gene-Edited Cell Medicines
July 28, 2021 Editas Medicine to Host Conference Call Discussing Second Quarter 2021 Results and Corporate Update
July 26, 2021 Editas Medicine Names Bruce E. Eaton, Ph.D., as Executive Vice President and Chief Business Officer
June 23, 2021 Editas Medicine Announces Enrollment of the First Pediatric Cohort in the BRILLIANCE Clinical Trial of EDIT-101 for the Treatment of LCA10 Following IDMC Endorsement
June 15, 2021 Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer
